Evidence method
Level · gp.fundamentals.debt_to_revenue
81.12% · OPTIONAL · NOT_ENOUGH_HISTORY
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
AKBA · Mar 31, 2025
Akebia Therapeutics, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001628280-25-023460General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
0.03% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-23.70% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Yoy · gp.fundamentals.revenue
75.84% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
34.41% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.gross_margin
86.70% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.operating_margin
23.57% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
17.01% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
3.81% · OPTIONAL · NOT_ENOUGH_HISTORY
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History12 statesHistory building
Sep 30, 20230/8 normalizedLevel 3Dec 31, 20230/8 normalizedLevel 3Mar 31, 20240/7 normalizedLevel 3Jun 30, 20240/7 normalizedLevel 3Sep 30, 20240/9 normalizedLevel 3Dec 31, 20240/9 normalizedLevel 3Mar 31, 20250/9 normalizedLevel 3Jun 30, 20250/9 normalizedLevel 3Sep 30, 20257/9 normalizedLevel 3Dec 31, 20257/9 normalizedLevel 3Mar 31, 20268/9 normalizedLevel 3Jun 30, 20268/9 normalizedLevel 3
Period transition
What moved in the state?
- Previous
- 24.16%
- Current
- 81.12%
- Delta
- 56.96%
- Previous
- 0.02%
- Current
- 0.03%
- Delta
- 0.01%
- Previous
- -25.38%
- Current
- -23.70%
- Delta
- 1.69%
- Previous
- -17.70%
- Current
- 75.84%
- Delta
- 93.54%
- Previous
- 10.14%
- Current
- 34.41%
- Delta
- 24.27%
- Previous
- 60.56%
- Current
- 86.70%
- Delta
- 26.14%
- Previous
- -31.51%
- Current
- 23.57%
- Delta
- 55.08%
- Previous
- 23.51%
- Current
- 17.01%
- Delta
- -6.49%
- Previous
- 4.85%
- Current
- 3.81%
- Delta
- -1.04%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · AKBA Fundamental State →Has State · Akebia Therapeutics, Inc. →Transitioned To · AKBA INVENTORY_PRESSURE_INCREASED →Transitioned To · AKBA MARGIN_INCREASED →Transitioned To · AKBA PROFITABILITY_INCREASED →Transitioned To · AKBA R_AND_D_INTENSITY_DECREASED →Transitioned To · AKBA SBC_INTENSITY_DECREASED →Transitioned To · AKBA Fundamental State →Transitioned To · AKBA BALANCE_SHEET_LEVERAGE_INCREASED →Transitioned To · AKBA CAPEX_INTENSITY_INCREASED →Transitioned To · AKBA CASH_GENERATION_INCREASED →Transitioned To · AKBA GROWTH_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.